Priavoid
Phase 2Developing a novel class of orally available all-D-peptide therapeutics that inhibit and reverse disease-specific protein aggregation in neurodegenerative disorders.
Founded
2017
Focus
RNA & Gene Therapy
About
Developing a novel class of orally available all-D-peptide therapeutics that inhibit and reverse disease-specific protein aggregation in neurodegenerative disorders.
Funding History
1Total raised: $25M
Series A$25MUndisclosedOct 15, 2021
Company Info
TypePrivate
Founded2017
LocationHamburg, Germany
StagePhase 2
Contact
SIMILAR COMPANIES
300Microns
Pre-clinical · Munich
BetaSense
Pre-clinical · Berlin
AB Diagnostic Systems
Pre-clinical · Jena
bbi-biotech
Pre-clinical · Berlin
Mireca Medicines
Pre-clinical · Munich
Is this your company?
Claim your profile to update information, add pipeline data, and connect with investors.
Claim profile